nach oben

American Journal of Cardiovascular Drugs

11.05.2024 | Systematic Review

Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials

verfasst von: Gustavo de Oliveira Almeida, Thiago Faraco Nienkötter, Caroline Cristine Almeida Balieiro, Eric Pasqualotto, Júlia Braga Cintra, Henrique Champs Porfírio Carvalho, Ana Laura Soares Silva, Júlia Camargo Kabariti, Bárbara Silvestre Minucci, Edmundo Damiani Bertoli, Camila Mota Guida

Erschienen in: American Journal of Cardiovascular Drugs

Einloggen, um Zugang zu erhalten

Abstract

Background

GLP-1 receptor agonists (GLP-1 RAs) have emerged as an effective therapeutic class for weight loss. However, the efficacy of these agents in reducing cardiovascular endpoints among patients living with obesity or overweight is unclear.

Methods

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1 RAs versus placebo in patients with obesity or overweight. We searched PubMed, Cochrane, and Embase databases. A random-effects model was used to calculate risk ratios (RRs) and mean differences (MDs), with 95% confidence intervals (CIs).

Results

A total of 13 RCTs were included, with 30,512 patients. Compared with placebo, GLP-1 RAs reduced systolic blood pressure (MD − 4.76 mmHg; 95% CI − 6.03, − 3.50; p < 0.001; I² = 100%) and diastolic blood pressure (MD − 1.41 mmHg; 95% CI − 2.64, − 0.17; p = 0.03; I² = 100%). GLP-1 RA significantly reduced the occurrence of myocardial infarction (RR 0.72; 95% CI 0.61, 0.85; p < 0.001; I² = 0%). There were no significant differences between groups in unstable angina (UA; RR 0.84; 95% CI 0.65, 1.07; p = 0.16; I² = 0%), stroke (RR 0.91; 95% CI 0.74, 1.12; p = 0.38; I² = 0%), atrial fibrillation (AF; RR 0.49; 95% CI 0.17, 1.43; p = 0.19; I² = 22%), and deep vein thrombosis (RR 0.30; 95% CI 0.06, 1.40; p = 0.13; I² = 0%).

Conclusions

In patients living with obesity or overweight, GLP-1 RA reduced systolic and diastolic blood pressure and the occurrence of myocardial infarction, with a neutral effect on the occurrence of UA, stroke, AF, and deep vein thrombosis.

Registration

PROSPERO identifier number CRD42023475226.

Nur mit Berechtigung zugänglich

Elagizi A, Kachur S, Carbone S, et al. A review of obesity, physical activity, and cardiovascular disease. Curr Obes Rep. 2020;9(4):571–81. https://doi.org/10.1007/s13679-020-00403-z.CrossRefPubMed

Tong Y, Xu S, Huang L, et al. Obesity and insulin resistance: pathophysiology and treatment. Drug Discov Today. 2022;27(3):822–30. https://doi.org/10.1016/j.drudis.2021.11.001.CrossRefPubMed

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98. https://doi.org/10.1038/s41574-019-0176-8.CrossRefPubMed

Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146. https://doi.org/10.1161/CIR.0000000000000485.CrossRefPubMedPubMedCentral

Safaei M, Sundararajan EA, Driss M, et al. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136: 104754. https://doi.org/10.1016/j.compbiomed.2021.104754.CrossRefPubMed

Bergmann NC, Davies MJ, Lingvay I, et al. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023;25(1):18–35. https://doi.org/10.1111/dom.14863.CrossRefPubMed

Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (Lausanne). 2021;6(12): 706978. https://doi.org/10.3389/fendo.2021.706978.CrossRef

Powell-Wiley TM, Poirier P, Burke LE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–1010. https://doi.org/10.1161/CIR.0000000000000973.CrossRefPubMedPubMedCentral

Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171–92. https://doi.org/10.1007/5584_2020_496.CrossRefPubMed

10.

Kadouh H, et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105(5):1552–63. https://doi.org/10.1210/clinem/dgz140.CrossRefPubMed

11.

Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther. 2020;45 Supp 1(Suppl 1):17–27. https://doi.org/10.1111/jcpt.13230.CrossRef

12.

Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.CrossRefPubMed

13.

Mantovani A, Petracca G, Beatrice G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73. https://doi.org/10.3390/metabo11020073.CrossRefPubMedPubMedCentral

14.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372: n71. https://doi.org/10.1136/bmj.n71.CrossRef

15.

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366:14898. https://doi.org/10.1136/bmj.l4898.CrossRef

16.

Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–6. https://doi.org/10.1016/j.jclinepi.2007.11.010.CrossRefPubMed

17.

Schünemann H, Brożek J, Guyatt G, et al. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. doi: https://doi.org/10.1136/bmj.39500.677199.AE.

18.

Review Manager (RevMan)[Computer Program]. Version 5.1. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2011. https://training.cochrane.org/online-learning/core-software/revman.

19.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2.CrossRefPubMed

20.

Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.

21.

Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–16. https://doi.org/10.1016/S0140-6736(09)61375-1.CrossRefPubMed

22.

Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36(10):3276–82. https://doi.org/10.2337/dc13-0354.CrossRefPubMedPubMedCentral

23.

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–51. https://doi.org/10.1038/ijo.2013.120.CrossRefPubMed

24.

Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310–9. https://doi.org/10.1038/ijo.2016.52.CrossRefPubMed

25.

O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–49. https://doi.org/10.1016/S0140-6736(18)31773-2.CrossRefPubMed

26.

Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183.CrossRefPubMed

27.

Wadden TA, Bailey TS, Billings LK, et al. STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13. https://doi.org/10.1001/jama.2021.1831.CrossRefPubMed

28.

Rubino D, Abrahamsson N, Davies M, et al. STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–25. https://doi.org/10.1001/jama.2021.3224.CrossRefPubMed

29.

Rubino DM, Greenway FL, Khalid U, et al. STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–50. https://doi.org/10.1001/jama.2021.23619.CrossRefPubMedPubMedCentral

30.

Knop FK, Aroda VR, do Vale RD, et al. OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705–19. https://doi.org/10.1016/S0140-6736(23)01185-6.CrossRefPubMed

31.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. https://doi.org/10.1056/NEJMoa2206038.CrossRefPubMed

32.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. https://doi.org/10.1056/NEJMoa2307563.CrossRefPubMed

33.

Monney M, et al. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023;49(5):101470. https://doi.org/10.1016/j.diabet.2023.101470.CrossRefPubMed

34.

Guo X, et al. The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese patients without diabetes: a systematic review and meta-analysis. Hormone and metabolic research. Hormone Metab Res. 2022;54(7):458–71. https://doi.org/10.1055/a-1844-1176.CrossRef

35.

Liu Y, et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023;118(3):614–26. https://doi.org/10.1016/j.ajcnut.2023.04.017.CrossRefPubMed

36.

Alkhezi OS, et al. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obesity Rev. 2023;24(3):e13543. https://doi.org/10.1111/obr.13543.CrossRef

37.

DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10:364–76. https://doi.org/10.1038/nrendo.2014.44.CrossRefPubMedPubMedCentral

38.

Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7. https://doi.org/10.1016/j.phrs.2017.05.013.CrossRefPubMed

39.

Sivertsen J, Rosenmeier J, Holst JJ, et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9(4):209–22. https://doi.org/10.1038/nrcardio.2011.211.CrossRefPubMed

40.

Goud A, et al. GLP-1 Agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18(2):16. https://doi.org/10.1007/s11906-015-0621-6.CrossRefPubMed

41.

Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463–74. https://doi.org/10.1038/s41569-023-00849-3.CrossRefPubMed

42.

Artham SM, Lavie CJ, Milani RV, et al. Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. Ochsner J. 2009 Fall;9(3):124–32.

43.

Jaacks LM, Vandevijvere S, Pan A, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7:231–40. https://doi.org/10.1016/S2213-8587(19)30026-9.CrossRefPubMedPubMedCentral

44.

Preda A, Carbone F, Tirandi A, et al. Obesity phenotypes and cardiovascular risk: from pathophysiology to clinical management. Rev Endocr Metab Disord. 2023;24:901–19. https://doi.org/10.1007/s11154-023-09813-5.CrossRefPubMedPubMedCentral

45.

Gadde KM, et al. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. https://doi.org/10.1016/j.jacc.2017.11.011.CrossRefPubMedPubMedCentral

46.

Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–36. https://doi.org/10.1016/S0140-6736(21)00590-0.CrossRef

47.

Marx N, Husain M, Lehrke M, et al. GLP-1 Receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022. https://doi.org/10.1161/CIRCULATIONAHA.122.059595.CrossRefPubMedPubMedCentral

48.

Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021. https://doi.org/10.7150/ijbs.59965.CrossRefPubMedPubMedCentral

49.

Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc. 2019. https://doi.org/10.1016/j.pcad.2019.07.005.CrossRef

50.

Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc. 2020. https://doi.org/10.1093/cvr/cvz323.CrossRef

51.

Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. Br Med J. 2024;29(384): e076410. https://doi.org/10.1136/bmj-2023-076410.CrossRef

52.

Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225-241.e8. https://doi.org/10.1016/j.clinthera.2014.11.008.CrossRefPubMed

53.

Ansari HUH, Qazi SU, Sajid F, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract. 2024;30(2):160–71. https://doi.org/10.1016/j.eprac.2023.11.007.CrossRefPubMed

54.

Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022;27(13):4315. https://doi.org/10.3390/molecules27134315.CrossRefPubMedPubMedCentral

55.

Forzano I, Varzideh F, Avvisato R, et al. Tirzepatide: a systematic update. Int J Mol Sci. 2022;23(23):14631. https://doi.org/10.3390/ijms232314631.CrossRefPubMedPubMedCentral

Titel: Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials
verfasst von: Gustavo de Oliveira Almeida
Thiago Faraco Nienkötter
Caroline Cristine Almeida Balieiro
Eric Pasqualotto
Júlia Braga Cintra
Henrique Champs Porfírio Carvalho
Ana Laura Soares Silva
Júlia Camargo Kabariti
Bárbara Silvestre Minucci
Edmundo Damiani Bertoli
Camila Mota Guida
Publikationsdatum: 11.05.2024
Verlag: Springer International Publishing
Erschienen in: American Journal of Cardiovascular Drugs
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-024-00647-3

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials

Abstract

Background

Methods

Results

Conclusions

Registration

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie